Vídeo resumen apertura
Highlights
Basado en hechos reales y Q&A
Sesión completa
¿Quiere saber más sobre la HPN?
Haz click aquí
Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.
Para acceder al contenido mínimo de la Ficha Técnica de Soliris® Julio 2023, haz click aquí
1. Kulasekararaj AG, Hill A, RoLnghaus ST, et al. Blood. 2019;133(6):540-49. 2. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Blood. 2019;133(6):530-539. 3. Brodsky RA, Peffault de Latour R, RoLnghaus ST, et al. Haematologica. 2021;106(1):230-237. 4. Schrezenmeier H, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Therapeutic Advances in Hematology. 2020;11:1-14. >5. Tanaka K, Adams B, Aris A, Fujita N, Ogawa M, Ortiz S et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatric Nephrology. 2020; 36(4):889-898. 6. Ariceta G, Dixon B, Kim S, Kapur G, Mauch T, Ortiz S et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney International. 2021; 100(1):225-237. 7. Rondeau, E., Scully, M., Ariceta, G., et al., 2020. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney International, 97(6), pp.1287-1296.
ES/ULT-a/0119 diciembre 2022
Highlights
Sesión completa
¿Quiere saber más sobre el SHUa?
Haz click aquí
Retos y futuro en enfermedades raras
Hospital Universitario 12 de Octubre, Madrid
Un nuevo horizonte para los pacientes con SHUa y HPN
Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.
Para acceder al contenido mínimo de la Ficha Técnica de Soliris® noviembre 2022, haz click aquí
1. Kulasekararaj AG, Hill A, RoLnghaus ST, et al. Blood. 2019;133(6):540-49. 2. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Blood. 2019;133(6):530-539. 3. Brodsky RA, Peffault de Latour R, RoLnghaus ST, et al. Haematologica. 2021;106(1):230-237. 4. Schrezenmeier H, et al. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Therapeutic Advances in Hematology. 2020;11:1-14. >5. Tanaka K, Adams B, Aris A, Fujita N, Ogawa M, Ortiz S et al. The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatric Nephrology. 2020; 36(4):889-898. 6. Ariceta G, Dixon B, Kim S, Kapur G, Mauch T, Ortiz S et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney International. 2021; 100(1):225-237. 7. Rondeau, E., Scully, M., Ariceta, G., et al., 2020. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney International, 97(6), pp.1287-1296.
ES/ULT-a/0119 diciembre 2022
